204 related articles for article (PubMed ID: 33180250)
21. An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic.
Opal S; File TM; van der Poll T; Tzanis E; Chitra S; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S40-S47. PubMed ID: 31367740
[TBL] [Abstract][Full Text] [Related]
22. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
Agarwal SK; Tong B; Bueno OF; Menon RM; Salem AH
Adv Ther; 2018 Nov; 35(11):2015-2023. PubMed ID: 30264382
[TBL] [Abstract][Full Text] [Related]
23. Impact of P-gp inhibition on systemic exposure of pralsetinib and dosing considerations.
Suchomel J; Agarwal P; Anders D; Hughes K; Tang Y; Sane R; Scalori A; Sharma S; Cheeti S
Clin Transl Sci; 2024 Jun; 17(6):e13818. PubMed ID: 38807449
[TBL] [Abstract][Full Text] [Related]
24. Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis.
Gill CM; Fratoni AJ; Shepard AK; Kuti JL; Nicolau DP
J Antimicrob Chemother; 2022 Apr; 77(5):1372-1378. PubMed ID: 35194643
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats.
Lin W; Flarakos J; Du Y; Hu W; He H; Mangold J; Tanaka SK; Villano S
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821446
[TBL] [Abstract][Full Text] [Related]
26. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Tanaka SK; Steenbergen J; Villano S
Bioorg Med Chem; 2016 Dec; 24(24):6409-6419. PubMed ID: 27469981
[TBL] [Abstract][Full Text] [Related]
27. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
O'Riordan W; Green S; Overcash JS; Puljiz I; Metallidis S; Gardovskis J; Garrity-Ryan L; Das AF; Tzanis E; Eckburg PB; Manley A; Villano SA; Steenbergen JN; Loh E
N Engl J Med; 2019 Feb; 380(6):528-538. PubMed ID: 30726689
[TBL] [Abstract][Full Text] [Related]
28. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Chopra T; Sandhu A; Theriault N; Meehan J; Tillotson G
Future Microbiol; 2020 Sep; 15():1319-1333. PubMed ID: 32959689
[TBL] [Abstract][Full Text] [Related]
29. Omadacycline for Acute Bacterial Skin and Skin Structure Infections.
Abrahamian FM; Sakoulas G; Tzanis E; Manley A; Steenbergen J; Das AF; Eckburg PB; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S23-S32. PubMed ID: 31367742
[TBL] [Abstract][Full Text] [Related]
30. The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
Zhu T; Howieson C; Wojtkowski T; Garg JP; Han D; Fisniku O; Keirns J
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):548-555. PubMed ID: 28301084
[TBL] [Abstract][Full Text] [Related]
31. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Mendell J; Zahir H; Matsushima N; Noveck R; Lee F; Chen S; Zhang G; Shi M
Am J Cardiovasc Drugs; 2013 Oct; 13(5):331-42. PubMed ID: 23784266
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study.
Overcash JS; Bhiwandi P; Garrity-Ryan L; Steenbergen J; Bai S; Chitra S; Manley A; Tzanis E
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858208
[TBL] [Abstract][Full Text] [Related]
33. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
34. Effects of verapamil on the pharmacokinetics of puerarin in rats.
Zhou Y; Song X; Dong G
Xenobiotica; 2019 Oct; 49(10):1178-1182. PubMed ID: 30173622
[TBL] [Abstract][Full Text] [Related]
35. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline.
Flarakos J; Du Y; Gu H; Wang L; Einolf HJ; Chun DY; Zhu B; Alexander N; Natrillo A; Hanna I; Ting L; Zhou W; Dole K; Sun H; Kovacs SJ; Stein DS; Tanaka SK; Villano S; Mangold JB
Xenobiotica; 2017 Aug; 47(8):682-696. PubMed ID: 27499331
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects.
Yang H; Huang Z; Chen Y; Zhu Y; Cao G; Wang J; Guo Y; Yu J; Wu J; Liu L; Deng J; Liu J; Reinhart H; Zhang J; Wu X
Front Pharmacol; 2022; 13():869237. PubMed ID: 35529438
[No Abstract] [Full Text] [Related]
37. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
38. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
39. Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects.
Darpo B; Xue H; Tanaka SK; Tzanis E
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405867
[TBL] [Abstract][Full Text] [Related]
40. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
